Kardigan, Inc. KARD

Annual Quarterly

Q2 FY2026 YTD · ended Jun 30, 2026 · Revenue $0 · Filed Aug 11, 2026

Kardigan, Inc. (KARD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In the fiscal 2026 year to date through Jun 30, 2026, it reported revenue of $0 and a net loss of $116.2 million. Free cash flow was -$109.4 million. As of Jun 30, 2026 it held $660.7 million in cash and investments and $13.3 million in total debt.

Revenue
$0
Net income
$-116.24M
Operating cash flow
$-107.33M
Free cash flow
$-109.42M
EPS
$-4.61
Dividend per share
None
Shares outstanding
93.50M
Net cash
$647.35M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KARD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
2123613

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026 YTD
Jun 30, 2026
Revenue
$0
Operating income
-$118.8M
Net income
-$116.2M
Diluted EPS
-$4.61
Operating cash flow
-$107.3M
Free cash flow
-$109.4M
Total assets
$721.8M
Total liabilities
$106.3M
Stockholders' equity
$615.5M
Cash and investments
$660.7M
Total debt
$13.3M

Recent SEC filings

Form Description Filed Period
8-K Current report
Officer or director change, Regulation FD disclosure
 Sep 30, 2026 Sep 29, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
8-K Current report
Bylaw or fiscal year change
 Jun 23, 2026 Jun 22, 2026

All 54 Kardigan, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.